BioLine Rx BLRX is set to give its latest quarterly earnings report on Wednesday, 2023-08-30. Here's what investors need to know before the announcement.
Analysts estimate that BioLine Rx will report an earnings per share (EPS) of $-0.11.
BioLine Rx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at BioLine Rx's past performance and the resulting price change:
| Quarter | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.14 | -0.11 | -0.07 | |
| EPS Actual | -0.1 | -0.08 | -0.15 | -0.15 |
| Price Change % | -0.64% | 1.3% | -1.47% | -5.03% |
Stock Performance
Shares of BioLine Rx were trading at $1.28 as of August 28. Over the last 52-week period, shares are down 13.0%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for BioLine Rx visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
